Letters Section Editor: Stephen J. Lurie,
MD, PhD, Senior Editor.
To the Editor: In their cost-effectiveness
analysis, Dr Salomon and colleagues1 found
that newer treatment options for hepatitis C virus (HCV) infection appear
to be reasonably cost-effective. These results, however, varied widely across
different patient subgroups and were reflected largely in quality of life
rather than increased survival. These conclusions were based on a Markov model
in a theoretical cohort of 40-year-old patients with abnormal alanine aminotransferase
levels, detectable serum HCV RNA, and a liver biopsy revealing no fibrosis.
Bernstein D. Cost-effectiveness of Treatment for Chronic Hepatitis C Infection. JAMA. 2003;290(15):1993-1994. doi:10.1001/jama.290.15.1993-a